Frontlight ResearchEarly access
TerminatedNo phase
Real-World Study of Ceftazidime Avibactam in China
Key facts
- Who runs it
- Pfizer
- Where
- China17 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 220 people enrolled
- Started
- 20 Oct 2022
- Ended
- 11 Jul 2024
- Type of study
- Observational
- Treatments tested
- ceftazidime avibactam group
- Record updated
- 4 September 2025
- Why it stopped
- The study was prematurely discontinued due to slow enrollment and strategic considerations. This decision was not based on any safety or efficacy concerns.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Initiate ≥1 dose of ceftazidime-avibactam during hospitalization
- Aged ≥ 18 years old at the time of the informed consent signature
- Provide signed informed consent. Exclusion criteria:
- Are enrolled in any clinical trial, including enrollment in non interventional studies
- Pregnant women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational study will enroll approximately 450 in patients. Patients treated with CAZ AVI for at least 1 dose at around 20 research centers in China will be enroll.
The group in the trial
- ceftazidime avibactam group
Receive ≥1 dose of ceftazidime avibactam in routine practice; Aged ≥ 18 years old at the time of the informed consent signature.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice
- Record updated
- 4 September 2025